Latest News

FDA approves gene therapy for ultra-rare childhood metabolic disease, will cost $4m per patient
FDA approves gene therapy for ultra-rare childhood metabolic disease, will cost $4m per patient
The approval is a landmark moment for Sanfilippo patients who face progressive neurological symptoms and premature death.
Subscribe to Our Topic-Specific Newsletters
From Partnering and Investment insights to Scientific developments to Commercialization strategies, sign up to receive free to your mailbox
Watch the latest videos from partnering events

play_arrow
Sponsored Content
Where Are Large Pharmas Placing Their Bets?
Where Are Large Pharmas Placing Their Bets?

Now playing
play_arrow04:08
Sponsored Content
Where Are Large Pharmas Placing Their Bets?
Where Are Large Pharmas Placing Their Bets?

Now playing
play_arrow03:45
Sponsored Content
Ribbon Bio: Unlocking New Possibilities with Pristine Synthetic DNA
Ribbon Bio: Unlocking New Possibilities with Pristine Synthetic DNA

Now playing
play_arrow02:55
Sponsored Content
A Match for Success - Germany!
A Match for Success - Germany!

Now playing
play_arrow04:35
Sponsored Content
Pioneering Drug Discovery with Evotec
Pioneering Drug Discovery the Evotec Way

Now playing
play_arrow04:34
Sponsored Content
Interview with Nicholas Shackley, CEO of Gannet BioChem
Interview with Nicholas Shackley, CEO of Gannet BioChem

Now playing
play_arrow08:37
HOTH Therapeutics Presents Early Stage Oncology, Dermatology and Neurology Pipeline
HOTH Therapeutics Presents Early Stage Oncology, Dermatology and Neurology Pipeline

Now playing
play_arrow15:12
Immuneering: Atebimetinib MEK Inhibitor for Pancreatic Cancer
Immuneering: Atebimetinib MEK Inhibitor for Pancreatic Cancer







.jpg?width=300&auto=webp&quality=80&disable=upscale)

.png?width=1400&auto=webp&quality=80&disable=upscale)

.jpg?width=1400&auto=webp&quality=80&disable=upscale)




.jpg?width=1400&auto=webp&quality=80&disable=upscale)






